Latest News

(UroToday.com) Upfront cytoreductive nephrectomy is no longer recommended in patients treated with tyrosine kinase inhibitors since the CARMENA trial.1 Response of the primary tumor in mRCC has been described in the TKI era but remains unknown with immune checkpoint inhibitors. At the ESMO 2020 virtual annual meeting, Dr. Jean Courcier and colleagues presented results of their […]

(UroToday.com) Non-clear cell renal cell carcinoma (nccRCC) encompasses a heterogeneous group of histologies comprising ∼25% of all RCC diagnoses with worse outcomes than clear cell RCC. Cabozantinib inhibits receptor tyrosine kinases that regular tumor cell growth, angiogenesis, and immune cell function, including MET, VEGFR, and the TAM family of kinases (TYRO3, AXL, and MER). Cabozantinib is […]

(UroToday.com) Patients with metastatic hormone-sensitive prostate cancer (mHSPC) who have visceral metastases have shown to have worse overall survival (OS). Visceral metastases, most commonly in the lungs and liver, are uncommon (<20%) in men with mHSPC. The addition of abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) in the phase 3 LATITUDE study […]

(UroToday.com) It is well known that inflammation is a hallmark of cancer, harboring a critical role in tumor development and metastatic progression in many cancers, including prostate cancer.1 It has been shown that baseline neutrophil-to-lymphocyte ratio (NLR), calculated by dividing the absolute peripheral neutrophil count by the absolute lymphocyte count, is an accessible and inexpensive marker of […]

(UroToday.com) Prostate cancer (PC) is the second most diagnosed cancer and the sixth leading cause of cancer death among men worldwide. If detected at an early stage, it can be managed by active surveillance, surgery, or radiotherapy. However, 25% of patients will present with or will progress to metastatic PC.1 Most metastatic patients (80%) will harbor bone […]

(UroToday.com) In the phase III PROfound study, olaparib lead to significantly longer radiographic progression-free survival compared with physician’s choice of next-generation hormonal agent (control) in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC) and alterations in homologous recombination repair (HRR) genes.1 The study protocol allowed patients in the control arm who experienced radiographic disease progression […]

(UroToday.com) The principal objectives of TRACERx Renal consortium are to define drivers and intra-tumor heterogeneity in renal cell carcinoma (RCC) and determine the relationship between heterogeneity and disease stage, clinical outcome, and treatment response. Additionally, other objectives include the identification of drivers of metastatic progression and drug response or resistance. Furthermore, it aims to establish the […]

(UroToday.com) Taxanes (docetaxel, cabazitaxel) and androgen-signaling-targeted inhibitors (abiraterone, enzalutamide) have shown survival benefits in metastatic castration resistant  prostate cancer (mCRPC), however until recently the optimal sequence of these treatments was unclear. In clinical practice, many patients with prostate cancer often receive sequential androgen-signaling-targeted inhibitors. Patients who have progressed on an androgen-signaling-targeted inhibitor may not respond […]

(UroToday.com) The increasing metastatic burden in prostate cancer has been shown to be associated with worsening prognosis in patients with advanced disease. To date, none of the current metastatic burden definitions consider metastatic lymph node volume, number, and distribution. In this presented study, the authors reported the results of an exploratory analysis of cross-sectional baseline […]

{{header-clinical-trials-navigation}} A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment Condition: Carcinoma, Renal Cell Study Type: Interventional Clinical […]